Biolex presents Locteron US Phase 2a hepatitis C data at EASL
... 2a clinical trial was conducted in 32 chronic hepatitis
C patients in the United States who had failed ... lead author on the trial. "As the treatment for hepatitis
C evolves there continues to be a need for a ... to improve patient care in the treatment of hepatitis
C through a more favorable side-effect profile ...
Scripps research team identifies key molecules that inhibit viral production
... amino acids) derived from the core protein of hepatitis
C. The team found that these peptides inhibit not ... said, "and it did."
The Problem with hepatitis
With over 170 million people infected ... at such prodigious rates. An RNA virus like hepatitis
C can mutate at a rate estimated as high as one ...
When acute hepatitis develops into chronic hepatitis
... to 7% of the world's population) have a chronic hepatitis
B infection. India is one of the countries, in which hepatitis
B is very common. A differentiation is made with ... of the disease between acute and chronic hepatitis
B. The most common symptom of an acute infection ...
Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
... and its clinical programs: ANA598 and ANA773 in hepatitis
C and ANA773 in cancer.
The presentation ... by developing novel medicines in the areas of hepatitis
C and oncology. For the treatment of chronic hepatitis
C, the Company is developing two potentially ...
Discovery could lead to a new animal model for hepatitis C
... During its career, the potentially fatal hepatitis
C virus has banked its success on a rather ... for the virus to enter nonhuman cells.
C virus exclusively targets human liver cells, ... human factors that could have been necessary for hepatitis
C virus entry. This work shows that's not the ...
Nano vaccine for hepatitis B shows promise for third world
... ANN ARBOR, Mich. Chronic hepatitis
B infects 400 million people worldwide, many of ... Even with three effective vaccines available, hepatitis
B remains a stubborn, unrelenting health problem, ... method for an antigen already used in existing hepatitis
B vaccines to activate the body's immune ....
Hepatitis C virus may need enzyme's help to cause liver disease
... PITTSBURGH, July 9 A key enzyme may explain how hepatitis
C infection causes fatty liver a buildup of ... elevated in human liver cells exposed to the hepatitis
C virus. While preliminary, the research suggests ... of FAS could help determine which patients with hepatitis
C virus may go on to develop more serious, ...
BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients
... of treatment. In the nucleoside-nave chronic hepatitis
B patients analyzed, no additional patient ... the rate of BARACLUDE resistance.
Many chronic hepatitis
B patients require long-term treatment. ... of Hong Kong.
Drug resistance occurs when the hepatitis
B virus (HBV) mutates, thereby avoiding the ...
New hope for hepatitis C sufferers
... vaccines and explore better treatment options for hepatitis
University of Adelaide virologists ... to develop new strategies to treat and prevent hepatitis
C, which infects more than 170 million people ... proteins that can be used in the fight against hepatitis
Currently there is no effective vaccine and ...
MIT: Why men are more prone to liver cancer
... but are rising rapidly, in part due to high hepatitis
C infection rates during the 1970s from blood ... Helicobacter hepaticus, which produces the same hepatitis
symptoms characteristic of human hepatitis
B and C.
In humans and mice, healthy males ...
Eltrombopag effective for hepatitis C patients with low blood-platelet counts
... NEW YORK (Dec. 28, 2007) -- For patients with hepatitis
C, having a low blood platelet count is a ... platelet counts and cirrhosis of the liver due to hepatitis
C virus (HCV) infection. Seventy-four percent of ... in the U.S. and 170 million worldwide carry the hepatitis
C virus. HCV is transmitted primarily by blood ...
Possible hepatitis C vaccine
C Virus (HCV) infects up to 500,000 people in the ... may be a significant step towards a vaccine.
C treatment is expensive and not successful in ... presented a paper Human antibodies to hepatitis
C virus potential for vaccine design at the ...
Who will recover spontaneously from hepatitis C virus infection
... More than 3% of world population is infected with hepatitis
C virus (HCV). The outcome of HCV infections is ... liver cancer. Since there is no cure for chronic hepatitis
C, nor is there any approved vaccine for this virus, hepatitis
C is currently a major health problem worldwide. ...
The hepatitis healing power of blueberry leaves
... leaves has shown a strong effect in blocking the replication of the hepatitis
C virus, opening up a new avenue for treating chronic HCV infections, ... lead to cirrhosis and liver cancer.
Among the areas of especially high hepatitis
C incidence is the Miyazaki prefecture of southern Japan, a trend that led ...
MicroRNAs grease the cell's circadian clockwork
... cholesterol and lipid metabolism and in aiding the replication of hepatitis
C virus" explains David Gatfield, one of Professor Schibler's ... circadian rhythms and miR-122 also extends to this microRNA's role in hepatitis
C virus replication", points out David Gatfield. Knowing whether viral ...
New guidelines for treating rheumatoid arthritis
... if RA patients have active bacterial infection, shingles (herpes-zoster), hepatitis
C and active or latent tuberculosis.
Doctors should not prescribe ...
Weill Cornell science briefs June/July 2008
Striking at the Heart of hepatitis
A New Drug May Wipe-Out Infection in More Patients
... are studying how a new drug might be used to treat chronic hepatitis
B infection (HBV). Clevudine is a compound that may provide a longer ...
Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
... in a Phase 1 human safety study of its experimental treatment for chronic hepatitis
B virus (HBV) infection, NUC B1000.
NUC B1000 ( ... in addition to viral titer, thereby reducing the destructive effects of hepatitis
and increasing the potential for resolution of viral infection.
Gene variation may elevate risk of liver tumor in patients with cirrhosis
... in individuals with cirrhosis, which may be caused by infection with the hepatitis
B or C viruses. There are currently no effective treatments for most HCC ... Among the 207 patients with cirrhosis, most of whom were infected with the hepatitis
C virus, 59 also had HCC. Patients with at least one copy of the G ...
New chimeric mouse model for human liver diseases, drug testing
... in the lab, which was a big hurdle for the study of viruses such as hepatitis
A and hepatitis
B, says senior author Inder Verma, Ph.D., a professor in the Laboratory of ...
American Society for Microbiology honors Jason T. Blackard
... focuses primarily on the molecular biology of co-infections of HIV and hepatitis
C. He has published over fourteen manuscripts since 2004, many as first ... of Public Health. He went on to complete his post doctoral fellowship in hepatitis
C pathogenesis within the Gastrointestinal Unit at Massachusetts General ...
Society for General Microbiology 161st Meeting, University of Edinburgh
... and waterborne pathogens and includes some fascinating presentations.
E virus (HEV), which can be fatal, was thought to be confined to China, ... microchips, novel insecticides and drug-producing sponge bacteria, hepatitis
C vaccine research, bacteriophage therapy and the control of coastal ...
First human gets new antibody aimed at hepatitis C virus
... the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the hepatitis
C virus (HCV).
The first volunteer received the antibody known as MBL-HCV1 on July 28, 2009, and the study is now proceeding and will eventually ...
Stem cell research: From molecular physiology to therapeutic applications
... "Grand Challenges in Global Health". He obtained $1.9 million for his proposal to use stem cells to create mouse models for testing HIV and hepatitis
C vaccines. Professor Deng has written a summary of recent progress in human embryonic and inducible pluripotent stem cell differentiation into ...
Liver disease 'shrunk' by blood-pressure drug
... University researchers analysed a small clinical trial of losartan, a drug normally prescribed for hypertension, on 14 patients in Spain, who had hepatitis
The illness was at an advanced stage causing fibrosis - scarring in the liver - which would usually have progressed to liver failure.
Five outstanding young gastroenterologists receive AGA Foundation 2009 Research Scholars Award
... Andrew Tai, MD, PhD, University of Michigan, Ann Arbor: Functional characterization of a novel role for a phosphatidylinositol 4-kinase in hepatitis
C virus replication
The prestigious Research Scholar Awards offer each scientist a total of $225,000 to help support his or her research over a ...
Visualizing virus replication in three dimensions
... an insight into the exact process of viral replication and serves as a model for other viruses whose replication is still unclear, such as the hepatitis
C virus. In addition, it offers new approaches for developing measures to prevent or treat dengue fever. Up to now, neither a vaccine nor a specific ...
Novel antibody prevents infection by hepatitis C virus
... Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the hepatitis
C virus (HCV). The new antibody effectively neutralized the virus in culture, and then prevented infection by the virus in a pre-clinical animal ...
Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
... movements and decreased levels of consciousness leading to coma.
Cirrhosis, which can cause AHE, occurs due to a variety of causes such as hepatitis
B and C infection, alcohol, and fatty liver associated with obesity and diabetes. It is estimated that there are up to 1 million cirrhosis patients ...
Team identifies a molecular switch linking infectious disease and depression
... rheumatoid arthritis, are more likely than others to become depressed. Some pro-inflammatory drugs, such as interferon-alpha, which is used to treat hepatitis
C and a cancer known as malignant melanoma, also induce symptoms of depression in a significant number of patients.
In the new study, mice were ...
New link in liver cancer
... Liver damage can be triggered by various insults, including hepatitis
infection or alcohol-induced cirrhosis. In severe cases, this damage can lead to cancer. A new study by researchers at the National Institutes of ...
Scots and Irish at greater risk of drink-related death, study shows
... but generally had lower rates of alcohol-related deaths. The higher rate of death from liver cancer could be attributable to the fact that viral hepatitis
is more common in ethnic minority communities.
The team used information on deaths for England and Wales from 1999 to 2003 and figures from the ...
Leeds research points to new therapy for hepatitis C treatment
... Combination therapies similar to those used for HIV patients may be the best way of treating hepatitis
C virus (HCV), say researchers from the University of Leeds.
A study of a protein called p7, has revealed that differences in the genetic coding ...
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
... PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
Bavituximab is in clinical trials for the treatment of hepatitis
C virus (HCV) infection and in preclinical development for the treatment of viral hemorrhagic fevers under a contract worth up to $44.4 million with ...
UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
... vaccine for HIV, which will have tremendous impact. Our work could also open the door for vaccines against other pathogens, such as West Nile virus, hepatitis
C and influenza. Even if we fail entirely, we will gain a great deal of insight into what we need to do to make mimetic vaccines work."
FSU researcher's discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
... begins to accumulate to unacceptable levels. The process can result from one of multiple causes, the most frequent of which are alcohol abuse and hepatitis
Fibrosis is difficult to detect until collagen deposits reach a point where the scarring has severely impaired organ function, ...
Body's anti-HIV drug explained
... innate ability to fight HIV.
"We were born with it, and it's there waiting," Chen said.
In addition to fighting HIV, APOBEC-3G can inhibit the hepatitis
B virus. Other members of the APOBEC family serve important roles in antibody maturation, fat metabolism and heart development.
Mapping the ...
RNA molecules, delivery system improve vaccine responses, effectiveness
... Singh and collaborators at M.D. Anderson Cancer Center in Houston, achieved their results during a two-year study primarily working with a DNA-based hepatitis
B vaccine. Their work was recently published in Molecular Therapy , the official journal of the American Society of Gene Therapy.
In their ...
Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway
... used, is highly efficacious in the treatment of external genital and anal warts, basal cell carcinoma, actinic keratoses, Kaposi's sarcoma, chronic hepatitis
C infection, and intraepithelial carcinoma. Therefore, the underlying mechanism of imiquimod action is of clinical importance. Imiquimod has been ...
American Society for Microbiology honors Regina S. Van Brakle
... not only in support of Walter Reed physicians and patients, but throughout the northeast region and beyond including providing quantitative hepatitis
C viral load testing to the entire Army. Furthermore, the laboratory has been deeply involved in the support of Operation Iraqi Freedom. In 2003, ....